Is there a potential for therapeutic drug monitoring of subcutaneously administered tocilizumab in patients with rheumatoid arthritis in daily practice?

Z. Layegh, F. Hooijberg, C. Bastida, A. D.R. Huitema, T. Rispens, C. G. Wolbink

Research output: Contribution to journalLetterpeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)664-665
Number of pages2
JournalClinical and experimental rheumatology
Issue number3
Publication statusPublished - 2022
Externally publishedYes

Cite this